In September, Gilead Sciences (NASDAQ:GILD) agreed to pay an eye-popping $US21 billion for Immunomedics (NASDAQ:IMMU), while Merck & Co (NYSE:MRK) committed $US4.2 billion to Seattle Genetics (NASDAQ:SGEN).
“The deals in the six months have been insane,” Campbell told *. “Where we are compared to a year ago, the number of deals is going through the roof.”
The Melbourne company’s research is much less far along than that Immunomedics or Seattle Genetics, as its tumour-fighting therapy still has not yet been tested in humans.
But Campbell said the Yale University-licensed drug is the first biologic drug that can cross the blood-brain barrier, binding to the nuclei of cancer cells and inhibiting what’s known as the DNA damage response (DDR) mechanism.
“It has a very unique way of killing cancer cells,” he said. “It really doesn’t matter what type of cancer is there.”
https://**promotion blocked**/health/which-cancer-fighting-biotech-will-be-the-next-race-oncology/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.167M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $13.07K | 8.35M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 205045293 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 111265026 | 40 |
View Market Depth
| Last trade - 16.10pm 16/09/2025 (20 minute delay) ? |
| PAB (ASX) Chart |